3 news items
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
RVMD
8 May 24
approaches with these RAS(ON) inhibitors. "The highly innovative investigational drug RMC-6236 continues to show
Revolution Medicines Announces Publications On The Discovery And Preclinical Profile Of Representative Of A New Class Of RAS(ON) Multi-Selective Inhibitors Designed To Block Full Spectrum Of Oncogenic RAS(ON) Proteins
RVMD
8 Apr 24
treatment regimen that may be capable of countering monotherapy drug resistance."This innovative research extends the impact of our tri
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
RVMD
8 Apr 24
monotherapy drug resistance. "This innovative research extends the impact of our tri-complex inhibitor platform to a wide
- Prev
- 1
- Next